US · Healthcare · Biotechnology
EPS came in at 0.01 against a street estimate of -0.05 — a beat of 120.0%.
Analysts rate Maravai Lifesciences Holdings Inc a buy (6 buy, 7 hold, 0 sell out of 13) with an average price target of $5.90.
| Fund | Stake |
|---|---|
| GTCR LLC | 13.66% |
| BRAIDWELL LP | 6.94% |
| BlackRock Inc | 6.34% |
| 12 West Capital Management LP | 4.92% |
| Mackenzie Investments | 4.28% |
| Vanguard Capital Management, LLC | 3.69% |
| Renaissance Technologies Corp | 2.89% |
| Tejara Capital Ltd | 2.37% |
| Document | Date |
|---|---|
| Material agreement · Q2 2026 | 2026-06-03 |
| Shareholder vote results · Q2 2026 | 2026-05-29 |
| Quarterly report · Q1 2026 | 2026-05-08 |
| Results announced · Q2 2026 | 2026-05-07 |
| Proxy statement · Q2 2026 | 2026-04-24 |
| Annual report FY2025 | 2026-02-26 |
| Results announced · Q1 2026 | 2026-02-25 |
| Quarterly report · Q3 2025 | 2025-11-07 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Maravai Lifesciences Holdings Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.